A novel delta opioid receptor biased agonist for Major Depressive Disorder

一种治疗重度抑郁症的新型 δ 阿片受体偏向激动剂

基本信息

  • 批准号:
    8316155
  • 负责人:
  • 金额:
    $ 15.44万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-08-15 至 2016-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): This project aims to discover and develop a new therapy for major depressive disorder (MDD), which affects 40 million people annually, profoundly reducing quality of life. Current treatments offer relief to only half of patients, and then only after weeks of treatment and with a high prevalence of adverse effects. Agonists of the delta-opioid receptor are antidepressant with rapid onset in rodents, and are analgesic and anxiolytic. They may offer a valuable new approach to treating MDD and in particular the sizeable fraction of MDD patients who also suffer anxiety or chronic pain. Unfortunately, delta-opioid agonists also cause convulsions in rodents and primates, which have thwarted drug development efforts to date; they also display transient efficacy limited by tolerance. However, recent data suggest that therapeutic, tolerizing, and convulsive effects of the delta-opioid receptor activation can be separated by a special class of agonist called "biased ligands", which selectively engage only a subset of the receptor signals normally stimulated by standard agonists. This project is based on a novel delta-opioid receptor biased ligand that potently and robustly activates therapeutic G protein signaling, but unlike standard agonists does not engage p-arrestin, which promotes tolerance and convulsions. This molecule is selective for the delta-opioid receptor and has characteristics appropriate for optimization into a new drug molecule. Through partnership with the NIH Blueprint for Neuroscience Grand Challenge, this project aims to engage iterative cycles of medicinal chemistry and biological testing in vitro and in vivo to derive a candidate drug with appropriate efficacy and safety to permit filing an Investigational New Drug application with the U.S. FDA and a Phase I clinical study to test pharmacokinetics, safety, and tolerability of the compound in normal volunteers. Successful completion of this project will deliver a compound with compelling preclinical proof of concept for a rapid onset antidepressant, potentially with anxiolytic and analgesic properties, with early clinical data to support testing in patients. This data will be ideal to attract further funding or partnership for further clinical trials and a New Drug Application to deliver a valuable new therapy to the millions of patients suffering from MDD.
描述(由申请人提供):该项目旨在发现和开发一种治疗重度抑郁症 (MDD) 的新疗法,该疾病每年影响 4000 万人,严重降低生活质量。目前的治疗方法只能使一半的患者得到缓解,而且只有在治疗数周后才能缓解,并且不良反应的发生率很高。 δ-阿片受体激动剂是在啮齿类动物中起效快的抗抑郁药,并且具有镇痛和抗焦虑作用。它们可能提供一种有价值的新方法来治疗重度抑郁症,特别是相当大一部分患有焦虑症或慢性疼痛的重度抑郁症患者。不幸的是,δ-阿片受体激动剂也会引起啮齿类动物和灵长类动物的惊厥,这阻碍了迄今为止的药物开发工作。它们还表现出受耐受性限制的短暂功效。然而,最近的数据表明,δ-阿片受体激活的治疗、耐受和惊厥作用可以通过一类称为“偏向配体”的特殊激动剂来分开,该激动剂仅选择性地参与通常由标准激动剂刺激的受体信号的子集。该项目基于一种新型 δ-阿片受体偏向配体,该配体能够有效且稳健地激活治疗性 G 蛋白信号传导,但与标准激动剂不同的是,它不会与 p-arrestin 结合,从而促进耐受性和惊厥。该分子对 δ-阿片受体具有选择性,并且具有适合优化为新药物分子的特性。通过与 NIH Blueprint for Neuroscience Grand Challenge 合作,该项目旨在进行体外和体内药物化学和生物测试的迭代循环,以获得具有适当功效和安全性的候选药物,以便向美国 FDA 提交研究性新药申请,并进行 I 期临床研究,以测试该化合物在正常志愿者中的药代动力学、安全性和耐受性。该项目的成功完成将提供一种化合物,该化合物具有令人信服的临床前概念证明,可用于快速起效的抗抑郁药,可能具有抗焦虑和镇痛特性,并具有早期临床数据支持患者测试。这些数据将非常适合吸引更多资金或合作伙伴进行进一步的临床试验和新药申请,从而为数百万患有重度抑郁症的患者提供有价值的新疗法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MICHAEL William LARK其他文献

MICHAEL William LARK的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MICHAEL William LARK', 18)}}的其他基金

A novel delta opioid receptor biased agonist for Major Depressive Disorder
一种治疗重度抑郁症的新型 δ 阿片受体偏向激动剂
  • 批准号:
    8522321
  • 财政年份:
    2011
  • 资助金额:
    $ 15.44万
  • 项目类别:
A novel delta opioid receptor biased agonist for Major Depressive Disorder
一种治疗重度抑郁症的新型 δ 阿片受体偏向激动剂
  • 批准号:
    8126874
  • 财政年份:
    2011
  • 资助金额:
    $ 15.44万
  • 项目类别:
A novel delta opioid receptor biased agonist for Major Depressive Disorder
一种治疗重度抑郁症的新型 δ 阿片受体偏向激动剂
  • 批准号:
    8540022
  • 财政年份:
    2011
  • 资助金额:
    $ 15.44万
  • 项目类别:
Selective modulation of GPCR signal transduction with biased ligands
使用偏向配体选择性调节 GPCR 信号转导
  • 批准号:
    7942893
  • 财政年份:
    2009
  • 资助金额:
    $ 15.44万
  • 项目类别:
Selective modulation of GPCR signal transduction with biased ligands
使用偏向配体选择性调节 GPCR 信号转导
  • 批准号:
    7855687
  • 财政年份:
    2009
  • 资助金额:
    $ 15.44万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 15.44万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 15.44万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 15.44万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 15.44万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 15.44万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 15.44万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 15.44万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 15.44万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 15.44万
  • 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
  • 批准号:
    RGPIN-2018-04753
  • 财政年份:
    2022
  • 资助金额:
    $ 15.44万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了